Miraculins Lead Programs LEAD PROGRAMS
PREVU® NON-INVASIVE CHOLESTEROL TEST –
Miraculins is currently working to launch
the novel, low cost, non-invasive,
point-of-care test which is a reliable
predictor of higher cholesterol
accumulation in the arteries and,
accordingly, a predictor of a patient’s risk of heart disease.
POTENTIAL MARKET: 540 million blood cholesterol tests are performed annually
world-wide
PREECLAMPSIA – Miraculins suite of markers for preeclampsia, discovered by
leading researchers at Mount Sinai Hospital and the Hospital for Sick Children,
are being advanced and commercialized through a collaborative research and
option agreement with Alere, Inc. (formerly Inverness Medical Innovations).
POTENTIAL MARKET: 6.4 million pregnant women per year in the US, greater than
134 million world-wide